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ABSTRACT
Objective: This study evaluated the validity of three sin-
gle-item, patient-rated, interviewer-administered, global
assessments of treatment benefit, satisfaction with treat-
ment and willingness to continue treatment, collectively
referred to as the BSW.
Methods: The BSW, micturition diaries, the Overactive
Bladder Questionnaire (OAB-q) and the King’s Health
Questionnaire (KHQ) were included in part or in total in
three OAB clinical trials. Discriminant validity for full
and dichotomized responses was assessed with ANOVAs
models and correlations were used to evaluate construct
validity.
Results: The BSW demonstrated significant differences
among the majority of the response levels on all measures
of micturitions in all studies. The BSW also demonstrated
discriminant validity with the OAB-q and the KHQ. BSW
measures demonstrated significant differences among the
change scores for all subscales of the OAB-q and the
majority of the KHQ domains with both full and dichot-
omized responses. Patients who were dissatisfied with
treatment and those unwilling to continue treatment also
reported significantly worse OAB-q and KHQ scores
compared with those who were satisfied with treatment
or willing to continue treatment. BSW measures were
moderately correlated with the micturition variables,
moderate to strongly correlated with the OAB-q and
weak to moderately with the KHQ, providing support for
the construct validity of the BSW measures.
Conclusions: The BSW is a useful tool to capture
patients’ global impressions of three key elements of treat-
ment outcome: a perceived benefit, satisfaction with treat-
ment, and the willingness to continue treatment, and can
facilitate patient–physician communication as well as be
informative to researchers.
Keywords: incontinence, overactive bladder, quality of
life, satisfaction, treatment benefit.
Introduction
Over the past decade, patient-reported outcomes
(PRO) have increasingly become accepted as impor-
tant measures of clinical outcome, particularly
when assessing symptom-based conditions such
as gastroesophageal reflux disease (GERD) [1],
migraine [2], or overactive bladder (OAB) [3,4].
The symptom complex of OAB, which includes uri-
nary urgency, with or without urge incontinence,
and usually with increased urinary frequency and
nocturia [5], has been shown to cause significant
symptom bother and to reduce health-related qual-
ity of life (HRQL) [2,6,7]. It is this symptom bother
and HRQL impairment that most commonly causes
patients with OAB to seek treatment. Thus, when
assessing treatment outcome, the patient’s subjec-
tive opinion is of paramount importance. Using
PROs when assessing OAB treatment enhances the
clinical evaluation of the treatment by assessing
changes in symptom bother and improvement or
declines in HRQL [8].
PROs such as HRQL and treatment satisfaction
have been assessed using multi-item and single-item
measures. Multi-item measures are a rich source of
information regarding the many facets of patient’s
lives that are affected by a condition (e.g., disease
impact on HRQL includes such domains as sleep,
physical and emotional function and social activi-
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ties). Generally, these measures include the patient’s
perspective and are designed on the basis of a sound
understanding of the ways a condition may affect
patients’ lives.
Nevertheless, single-item measures, such as both
physician- and patient-rated global assessments are
used routinely as an indicator of treatment out-
comes [9–12]. To provide a global assessment,
physicians’ evaluate multiple clinical factors, com-
paring these with their extensive clinical experience,
and provide an informed judgment. Typically,
patient-rated global assessments receive less consid-
eration; however, their usefulness should not be
underestimated. Patient-rated assessments reflect
the individual patient’s perspective by integrating
the various aspects of importance to them and pro-
viding a single outcome response. The aspects con-
sidered in the patient’s perspective may differ from
patient to patient, as it reflects the individual’s
needs, concerns, and values. Thus, the underlying
assumption of patient-rated global assessments is
that the patient will weigh all factors related to a
condition/disease (e.g., risk/benefit of a treatment;
consideration of multiple symptoms rather than one
symptom) and provide a response that reflects their
perspective of the construct being measured, just as
a physician would when providing a clinical global
assessment.
Patient-rated, global assessments of treatment
benefit, satisfaction with the treatment and willing-
ness to continue to use a treatment are often
considered in determinations of treatment effective-
ness. Patient perceptions of treatment benefit are
assumed to include an evaluation of the balance
between the experience of treatment risks and ben-
efits. Satisfaction with treatment is thought to
include an evaluation of the individual’s needs, per-
ceived benefit, concerns and expectations, thus con-
verting a complex construct into a global response.
Willingness to continue treatment, generally consid-
ered an indicator of future adherence, can be linked
to satisfaction and perceived benefit. Asking
patients questions regarding treatment benefit,
satisfaction, and willingness to continue facilitates
patient–physician communication and builds con-
sensus in treatment decisions. Nevertheless, many
physicians have had less confidence in these patient-
rated assessments because the validity of these
measures is rarely established.
The purpose of this research was to retro-
spectively evaluate the validity of three, single-
item, global assessments: collectively referred to as
the benefit, satisfaction, and willingness to con-
tinue (BSW) measure. This is important because a
validated, structured BSW measure can facilitate
physician efforts to gain an understanding of how
patients value their treatment. Additionally, the
BSW measure can provide a quick and conven-
ient way to determine if there are patient issues
related to their treatment that require additional
exploration.
Methods
The BSW was used in part or in total in three
recently completed large-scale, 12-week, rand-
omized, double-blind, placebo-controlled clinical
trials of tolterodine in the treatment of patients with
OAB (Table 1). All patients included in the studies
fulfilled the ICS criteria for a diagnosis of OAB syn-
drome including the presence of urinary frequency
of ≥8 micturitions/24 h and urgency with or with-
out urge incontinence. Patients participating in
Studies 1 and 2 had an additional requirement of
nocturia with an average of 2.5 or more nighttime
voids over a 7-day period. Patients from Study 3
had an additional requirement of urgency inconti-
nence with five or more episodes in a 7-day period.
Micturition characteristics were collected using a
patient diary. All patients were 18 years of age or
older and recruited without regard to sex. The stud-
ies were conducted in accordance with the Declara-
Table 1 Summary of tolterodine studies
Study 1 Study 2 Study 3
Sample size 596 555 1177
Location USA and Chile International International
7-day micturition diary Frequency, urgency
rating, nocturia
Frequency, urgency
rating, nocturia
Frequency, incontinence
episodes
Benefit ✓ ✓ ✓
Satisfaction ✓ ✓ NA
Willingness to continue ✓ ✓ NA
OAB-q ✓ (USA only) ✓ (Canada and USA 
only, n = 85)
NA
KHQ ✓ (Chile only) ✓ ✓
NA, not assessed.
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tion of Helsinki, local independent ethics
committee/institutional review board requirements,
and good clinical practice guidelines. Patients
provided written informed consent before study
entry.
Micturition Diary
A printed micturition diary was used to collect data
for the clinical efficacy assessments in all three tri-
als, although the structure varied slightly due to dif-
ferences in study design and end points. For all three
studies, patients recorded every micturition episode.
For Studies 1 and 2, patients recorded the time of
each micturition so that daytime and nighttime
voids could be discerned. Additionally, in Studies 1
and 2, patients rated their level of urgency associ-
ated with each micturition as follows:
1. No urgency: I felt no need to empty my bladder
but did so for other reasons.
2. Mild urgency: I could postpone voiding as long
as necessary without fear of wetting myself.
3. Moderate urgency: I could postpone voiding
for a short time without fear of wetting myself.
4. Severe urgency: I could not postpone voiding
but had to rush to the toilet in order not to wet
myself.
5. Urge incontinence: I leaked before arriving at
the toilet.
To account for both urinary frequency and
urgency severity ratings, an urgency-frequency
severity rating was calculated by summing each
urgency severity rating per day, which implicitly
reflects each patient’s urinary frequency. This rating
was analyzed as a continuous variable. Urgency
level was not assessed in Study 3.
Patient-Reported Outcome Measures
The benefit, satisfaction, and willingness to
continue measure. The BSW consists of three, sin-
gle-item measures designed to capture the patient’s
perception of the effect of treatment in terms of the
relative benefit, their satisfaction, and their inten-
tion or willingness to continue on therapy (Appen-
dix A). The Perception of Treatment Benefit
question asks patients if they perceived a benefit
from treatment. If the patient responds yes, the
patient is then asked if the perceived benefit was of
little benefit or much benefit. The Satisfaction
question is similar as patients are asked if they are
satisfied with treatment. If the response is yes, the
patient is then asked if they are a little satisfied or
very satisfied. If the response is no, the patient is
asked if they are a little dissatisfied or very dissat-
isfied. The Willingness to Continue question was
formatted in the same manner as the Satisfaction
question with the responses being a little bit willing
or very willing for yes responses and a little unwill-
ing or very unwilling for no responses. A neutral
mid-point was omitted to avoid ambiguous
responses. The BSW was administered by the
investigator or designated site personnel in the
local language as a standardized interview during
the follow-up visits. The BSW can potentially be
self-administered; however, this method of admin-
istration has not been tested. The PRO measures
were translated and validated according to
generally accepted translation guidelines [13] as
necessary.
Overactive  bladder  questionnaire  (OAB-q). The
OAB-q is a 33-item, disease-specific measure
designed to assess symptom bother and the impact
of OAB symptoms on HRQL [2]. The OAB-q con-
sists of a symptom bother scale and four HRQL
domains: Concern, Coping, Sleep, and Social inter-
actions. The OAB-q is a reliable and valid instru-
ment that can discriminate between normal and
clinically diagnosed continent and incontinent
patients with OAB. The scores are transformed into
a 0–100 scale. The Symptom Bother and HRQL
subscale scores are inversed with high scores on the
Symptom Bother scale indicating increased symp-
tom severity and high scores on the HRQL sub-
scales indicating better HRQL. The OAB-q has
been shown to be highly responsive to treatment
[8].
King’s health questionnaire (KHQ). The KHQ is a
33-item, multidimensional, disease specific, widely
used measure of HRQL and symptom severity in
patients with OAB and incontinence. Developed by
Kelleher and associates, the KHQ is the result of
several years of refinement in more than 1000
patients referred to a tertiary urogynecology unit
[6,14]. The KHQ consists of the following sum-
mated, multi-item HRQL domains: Role Limita-
tions, Physical Limitations, Social Limitations,
Personal Relationships, Emotions, Sleep and
Energy, and Severity (coping) Measures. In addi-
tion, two one-item questions address Incontinence
Impact and General Health Perceptions. The KHQ
also includes the multi-item Symptom Severity scale
that measures the severity of urinary symptoms.
The KHQ is a reliable and valid instrument that can
discriminate between normal and clinically diag-
nosed OAB patients [14,15]. The KHQ domains are
scored on a 0 (best) to 100 (worst) scale.
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Statistical Analysis
This validation analysis includes patients with both
baseline and follow-up clinical and PRO outcomes,
excluding patients with major protocol violations, as
decided before the randomization code was broken,
and patients withdrawn from the study. ANOVAs
(PROC GLM) were used to assess the ability of the
BSW scale to discriminate among changes in the mic-
turition diary variables, the OAB-q, and the KHQ
scores  over  12 weeks.  All  models  controlled  for
age and sex. Scheffe post hoc pairwise comparisons
were performed with P-values adjusted for multiple
comparisons. To examine the discrimination of
responses, the Satisfaction and Willingness to Con-
tinue questions were analyzed both by full response
options (i.e., four groups) and by collapsing
responses into dichotomous categories (i.e., satisfied/
dissatisfied and willing/unwilling). Spearman’s cor-
relation coefficients with the micturition variables,
the OAB-q, and the KHQ domains were also used to
evaluate construct validity of the BSW.
Results
The baseline demographics of the three studies var-
ied with what appears to be a slightly younger
cohort in Study 1 and more male patients in Studies
1 and 2 than in Study 3 (48.7%, 39.6%, and
20.2%, respectively) (Table 2). As expected based
on inclusion criteria, Study 3 patients reported a
greater number of incontinence episodes than Study
1 and 2 patients although statistical tests were not
performed.
Change in Micturitions
Table 3 shows that each of the BSW measures dem-
onstrated statistically significant differences among
the majority of the response levels on all measures
of micturitions in all studies. Patients who reported
“no treatment benefit” experienced a reduction
from baseline of less than one micturition per 24 h
for each of the studies compared with almost two
micturitions for those who reported “little benefit”
and approximately three micturitions for those per-
ceiving “much benefit” from their treatment. Addi-
tionally, those who were dissatisfied with treatment
also experienced a smaller reduction in micturition
frequency as did those unwilling to continue treat-
ment compared with those who were satisfied and
those willing to continue treatment.
Other micturition measures followed a similar
pattern. The mean changes in the number of night-
time voids were consistent across the two nocturia
studies: Study 1: −0.39 and Study 2: −0.30 for those
perceiving “no benefit,” Study 1: −0.80, and Study
2: −0.79 for those reporting “little benefit,” and
Study 1: −1.35 and Study 2: −1.41 for those report-
ing “much benefit” (Table 3). Similarly, those who
were dissatisfied with treatment also experienced a
smaller reduction in nighttime voids as did those
unwilling to continue treatment compared with
those who were satisfied and those willing to con-
tinue treatment. Table 3 also shows that patients in
Study 3 reported significantly fewer reductions in
incontinence episodes for those perceiving “no ben-
efit” compared with those reporting “little benefit”
or “much benefit.”
Overactive Bladder Questionnaire
Each of the BSW measures demonstrated discrimi-
nant validity based on the OAB-q results for Study
1 (Table 4). In this study, each of the BSW measures
demonstrated statistically significant differences
among the 12-week change scores for all subscales
of the OAB-q. For treatment benefit, all OAB-q
change from baseline scores were significantly
improved for those who perceived “much benefit”
compared with those who perceived “little” or “no
benefit.” The largest differences were observed in
the Sleep and Symptom Bother domains where the
Table 2 Baseline demographics of three studies
Study 1
N = 596
Study 2
N = 555
Study 3 
N = 1177
Age in years (SD) 58.4 (13.2) 60.6 (13.5)  61.0 (14.0)
Sex, n female (%)  306 (51.3)  335 (60.4) 939 (79.8)
Race
White, n (%)  511 (85.7)  508 (91.5) 1108 (94.1)
African American, n (%)  48 (8.1)  5 (0.9) 47 (4.0)
Other, n (%)  12 (2.0)  10 (1.8) 21 (1.9)
Missing, n (%)  25 (4.2)  32 (5.8) 1 (0.1)
Micturition frequency per 24/h (SD) 13.7 (3.3) 13.7 (4.2)  11.1 (3.8)
Incontinence episodes per 24/h (SD) 0.5 (1.2) 0.3 (0.9)  3.3 (3.1)
Nocturia episodes per night (SD) 3.5 (0.9) 3.7 (1.3) NA
Sum of urgency severity (SD) 269.8 (101) 265.6 (106) NA
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absolute differences in change scores between
“much benefit” and “no benefit” groups were 37.7
and 25.3 points, respectively. In Study 2, where only
85 patients provided responses to the OAB-q, the
absolute differences between Sleep and Symptom
bother change scores were similar (34.7 and 22.7
points, respectively). With the exception of the
Social Interaction subscale, most of the compari-
sons between benefit levels were statistically signif-
icant, although there were fewer statistically
significant differences between “no benefit” and
“little benefit” responses in this study than observed
in the larger Study 1.
Patients who were dissatisfied with treatment
also reported significantly lower OAB-q subscale
change scores compared with those who were sat-
isfied with treatment (Table 4). The largest differ-
ences were seen in the Sleep and Symptom Bother
subscale change scores; absolute differences of 23.2
and 16.3 points, respectively. The finding of signif-
icant differences among response levels was true
whether satisfaction was dichotomized as dissatis-
fied or satisfied, as in Table 4, or analyzed as the
original four levels of satisfaction, as in Table 5.
With the exception of the Social Interaction sub-
scale, the results from the Study 2 were similar,
although fewer comparisons between the levels of
dissatisfaction were statistically significant.
Findings for the willingness to continue treat-
ment measure were similar to the other BSW meas-
ures in that patients who were willing to continue
treatment reported significantly better OAB-q scale
score changes on all subscales (Table 4). Similarly,
the largest differences were seen in the Sleep,
Symptom Bother, and Concern subscales; absolute
differences of 22.4, 15.7, and 14.6 points, respec-
tively. For Study 2, all OAB-q subscale change
scores, with the exception of Social Interaction,
were significantly higher for those willing to con-
tinue treatment compared with those unwilling to
do so.
King’s Health Questionnaire
Each of the BSW measures demonstrated discrimi-
nant validity using the KHQ domains, with the
exception of General Health Perceptions and Per-
sonal Relationships in Study 3 (Tables 6 and 7).
Most KHQ domain changes from baseline to week
12 scores were significantly greater for those who
perceived higher levels of benefit compared with
those who perceived lower levels of benefit
(Table 6). The largest differences in change scores
were seen in the Incontinence Impact, Role Limita-
tions, and Physical Limitations domains (absoluteT
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differences between “much benefit” and “no bene-
fit” groups of 23.6, 23.2, and 23.2 points, re-
spectively; Table 6). For Study 2, 21 of the 27
comparisons, nine scales with three benefit compar-
isons, were statistically significant, with the com-
parison between “no benefit” versus “little benefit”
less frequently significant than observed in Study 3.
The largest differences in change scores were seen in
the Sleep/Energy and Incontinence Impact domains,
absolute differences between “much benefit” and
“no benefit” groups of 30.7 and 24.6 points, respec-
tively, in Study 2.
For the satisfaction with treatment measure,
Table 7 shows that all KHQ domain change scores
were greater for those who were satisfied compared
with those who were dissatisfied in Study 2. The
largest differences were seen in the Sleep/Energy,
Physical Limitation, and Incontinence Impact
domains; absolute differences of 20.9, 15.6, and
15.4 points, respectively. Similarly, all KHQ domain
Table 4 Study 1: OAB-q change scores by perception of treatment benefit at 12 weeks controlling for age and sex
OAB-q subscales
LS mean (SE)
Patient perception of treatment benefit†
Patient satisfaction with
treatment‡
Patient willingness to 
continue with treatment‡ 
No benefit
(N = 216)
Little benefit
(N = 165)
Much benefit
(N = 157)
Dissatisfied
(N = 199)
Satisfied
(N = 333)
Unwilling
(N = 207)
Willing 
(N = 331)
Symptom bother −4.1 (1.1) −16.3 (1.3) −29.4 (1.3)*** −5.3 (1.3) −21.6 (1.0)*** −5.7 (1.3) −21.4 (1.0)***
Coping 3.6 (1.3) 10.7 (1.5) 23.9 (1.6)** 4.5 (1.4) 16.1 (1.1)*** 5.2 (1.4) 15.7 (1.1)***
Concern 0.9 (1.3) 12.1 (1.4) 24.0 (1.5)*** 1.9 (1.4) 16.5 (1.0)*** 2.0 (1.3) 16.6 (1.0)***
Sleep 2.5 (1.5) 19.4 (1.7) 40.2 (1.8)*** 4.5 (1.7) 27.7 (1.3)*** 5.0 (1.7) 27.4 (1.3)***
Social interaction 0.5 (1.0) 4.7 (1.2) 10.7 (1.2)* 0.0 (1.0) 7.2 (0.8)** 0.8 (1.0) 6.8 (0.8)***
HRQL total scale 1.9 (1.1) 11.7 (1.2) 24.5 (1.3)*** 2.9 (1.2) 16.8 (0.9)*** 3.4 (1.2) 16.6 (0.9)***
†Pairwise comparison between means was performed using Scheffe’s test adjusting for multiple comparisons. All pairwise comparisons were significant P-values.
‡t-test comparison between dichotomous groups.
*P <0.05., **P <0.01, ***P <0.001.
Table 5 Study 1: OAB-q change scores by satisfaction with treatment at 12 weeks controlling for age and sex
OAB-q subscales
LS mean (SE)
Patient satisfaction with treatment 
Overall
F-value
P-values for
pairwise
comparisons†
Very dissatisfied
(N = 93)
A little dissatisfied
(N = 94)
A little satisfied
(N = 131)
Very satisfied
(N = 200)
Symptom bother −3.2 (1.8) −7.0 (1.8) −15.9 (1.5) −25.6 (1.2) 31.2*** 2***, 3***, 4**, 5***, 6***
Coping 2.0 (2.1) 7.0 (2.0) 10.2 (1.7) 19.9 (1.4) 17.0*** 2*, 3***, 5***, 6***
Concern −2.3 (1.9) 6.1 (1.9) 10.4 (1.6) 20.6 (1.3) 28.3*** 1*, 2***, 3***, 5***, 6***
Sleep 0.3 (2.4) 8.5 (2.4) 16.6 (2.0) 35.1 (1.6) 43.6*** 2***, 3***, 5***, 6***
Social interaction −1.5 (1.5) 1.3 (1.5) 3.9 (1.3) 9.2 (1.0) 11.0*** 3***, 5***, 6*
HRQL total scale −0.3 (1.7) 6.0 (1.6) 10.3 (1.4) 21.0 (1.1) 34.3*** 2***, 3***, 5***, 6***
†Pairwise comparison between means was performed using Scheffe’s test adjusting for multiple comparisons. 1 = very dissatisfied versus a little dissatisfied, 2 = very
dissatisfied versus a little satisfied, 3 = very dissatisfied versus very satisfied, 4 = a little dissatisfied versus a little satisfied, 5 = a little dissatisfied versus very satisfied,
and 6 = a little satisfied versus very satisfied.
*P <0.05, **P <0.01, ***P <0.001.
Table 6 Study 3: KHQ change scores by perception of treatment benefit at week 12 controlling for age and sex
KHQ subscales
LS mean (SE)
Patient perception of treatment benefit
P-values†
No benefit
(N = 370)
Little benefit
(N = 365)
Much benefit
(N = 440)
General health perception 1.7 (0.9) −0.8 (0.9) −2.2 (0.8) 2**
Incontinence impact −3.6 (1.4) −13.0 (1.4) −27.2 (1.3) 1***, 2***, 3***
Role limitations −5.2 (1.5) −12.8 (1.5) −28.4 (1.4) 1**, 2***, 3***
Physical limitations −2.0 (1.5) −12.2 (1.5) −25.2 (1.4) 1***, 2***, 3***
Social limitations −0.6 (1.2) −7.4 (1.2) −15.1 (1.1) 1***, 2***, 3***
Personal relationships −1.7 (1.7) −3.7 (1.8) −10.5 (1.6) 2**, 3*
Emotions −2.3 (1.3) −8.4 (1.3) −17.4 (1.2) 1**, 2***, 3***
Sleep/energy −2.3 (1.2) −8.4 (1.2) −14.1 (1.1) 1**, 2***, 3**
Severity measures −2.3 (1.1) −7.7 (1.1) −19.6 (1.0) 1, 2***, 3***
†Pairwise comparison between means was performed using Scheffe’s test adjusting for multiple comparisons. 1 = No benefit versus little benefit, 2 = No benefit ver-
sus much benefit, and 3 = little benefit versus much benefit.
*P <0.05, **P <0.01, ***P <0.001.
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change scores, except General Health Perception
and Personal Relationships, were higher for those
willing to continue treatment compared with those
unwilling to continue treatment (Table 7).
Correlations
Large, significant correlations demonstrating the
high intercorrelation of these three concepts were
found among all three BSW measures. The correla-
tion between the benefit and satisfaction measures
was 0.78 and 0.81 for Studies 1 and 2, respectively;
the correlation between the benefit and willingness
items was 0.74 for both studies; and the correlation
between the satisfaction and willingness items was
0.73 and 0.78 for Studies 1 and 2, respectively (all
P < 0.001).
The concurrent validity of the each of the BSW
measures was evaluated using correlations with
change from baseline to week 12 scores for mictu-
rition variables as well as OAB-q and KHQ quality
of life domains for all available variables in the
three studies (Table 8). Each of the BSW measures
were moderately correlated with the micturition
variables and all correlations were in the expected
direction. Correlations ranged from −0.40 to −0.44,
−0.33 to −0.44, and −0.29 to −0.40 for treatment
benefit, satisfaction with treatment and willingness
to continue treatment measures, respectively
(Table 6). With the exception of the Social Interac-
tion subscale, correlations among the BSW meas-
ures and the OAB-q were in the moderate to strong
range and in the expected direction, ranging from
0.33 to 0.55, 0.33 to 0.53, and 0.28 to 0.46 for
treatment benefit, satisfaction with treatment and
willingness to continue treatment measures, respec-
tively (Table 8). Correlations among the BSW meas-
ures and the KHQ were weak to moderate in
strength and in the expected direction. With the
exception of the General Health Perceptions
domain, the correlations ranged from −0.14 to
−0.45, −0.17 to −0.44, and −0.14 to −0.38 for treat-
ment benefit, satisfaction with treatment and will-
ingness to continue treatment measures,
respectively (Table 8).
Discussion
Symptom-based conditions require appropriate,
validated PRO measures to assess treatment effects.
Ideally, these measures should be short, easy to
complete, easy to interpret, and clinically meaning-
ful. Treatment benefit, satisfaction, and willingness
to continue a treatment are all attributes that a suc-
cessful treatment should possess. These measures
used alone or in combination are valuable in in-
formal clinical assessments and as end points in
research studies. Rarely, however, have they been
formally validated for these uses. In contrast, the
BSW is a valid outcome measure that demonstrated
consistency with both clinical outcomes and other
PRO measures across three separate OAB clinical
trials with varying patient populations.
Patient global assessments of treatment are sim-
ilar to clinician global assessments of treatment
benefit—except the point of view has changed. With
the BSW, there is an inherent assumption that the
patient weighs the risks and benefits of a treatment
to provide a global response. When considering
benefit, satisfaction, and willingness to continue,
patients balance such issues as amount of symptom
relief, life impact, side effects, drug costs, and con-
venience to provide their response. Although it may
appear redundant to ask all three BSW questions,
each question assesses a unique aspect of treatment
outcome. For example, one may perceive a treat-
ment benefit but not be satisfied with treatment due
to overriding side effects or dosing inconvenience.
Alternatively, one may perceive a benefit and be sat-
Table 7 Study 2: KHQ change scores by dichotomous satisfaction with treatment at 12 weeks controlling for age and sex
KHQ subscales
LS mean (SE)
Patient satisfaction
with treatment
Patient willingness to
continue with treatment
Dissatisfied
(N = 187)
Satisfied
(N = 322) P-values†
Unwilling
(N = 193)
Willing 
(N = 315) P-values
General health perception −0.4 (1.4) −4.0 (1.0) 0.04 −1.7 (1.4) −3.5 (1.1) 0.29
Incontinence impact −6.9 (2.3) −22.3 (1.7) <0.0001 −7.2 (2.2) −22.5 (1.7) <0.0001
Role limitations −2.4 (2.1) −17.3 (1.6) <0.0001 −4.2 (2.1) −16.4 (1.6) <0.0001
Physical limitations −0.4 (2.0) −16.0 (1.6) <0.0001 −2.1 (2.0) −15.4 (1.6) <0.0001
Social limitations 1.4 (1.6) −10.5 (1.3) <0.0001 −0.2 (1.6) −9.9 (1.3) <0.0001
Personal relationships −1.2 (2.0) −7.7 (1.5) 0.009 −2.0 (2.0) −7.1 (1.6) 0.05
Emotions −1.6 (1.7) −13.0 (1.3) <0.0001 −2.0 (1.7) −13.2 (1.3) <0.0001
Sleep/energy −0.1 (1.8) −21.0 (1.4) <0.0001 −0.8 (1.8) −20.8 (1.4) <0.0001
Severity measures −1.1 (1.3) −8.5 (1.0) <0.0001 −2.5 (1.3) −7.7 (1.0) 0.001
†Post hoc t-tests of least squares means between the two groups were performed.
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isfied because the balance of safety and efficacy is
favorable, but not be willing to continue a treat-
ment because the incremental benefit may not be
enough to merit continuation or the cost may be
prohibitive. Thus, responses to each question pro-
vide important information regarding perceived
outcome and behavioral intention that is needed to
assess treatment effectiveness, patient impact and
future compliance with therapy. Furthermore, a
negative response to one or more of the questions
provides an opportunity to explore the reasons in
greater detail.
The response options selected for each of the
BSW measures demonstrated acceptable properties
when evaluated using all levels or when collapsed
into dichotomous categories. When Satisfaction, for
example, was analyzed using all four responses, it
was interesting to find that although the discrimi-
nation between “very satisfied” and “a little satis-
fied” was very clear, the discrimination between “a
little satisfied” and “a little dissatisfied” was much
less evident. Thus, the polar ends of the Satisfaction
and Willingness scales were highly discriminative,
whereas the middle options were more of a “gray
area” for patients. The data were also analyzed as a
dichotomous response by combining the similar
responses (i.e., very satisfied/a little satisfied vs. very
dissatisfied/a little dissatisfied) which yielded greater
discrimination for both the Satisfaction and Will-
ingness items.
As with any new measure, there are limitations
to consider. For example, the implications of the
unbalanced nature of the Benefit response scale
have not been fully explored. Although the scaling
is weighted toward positive responses with two
responses for benefit and one for no benefit, there
may be some rationale to ask how great the failure
if no benefit is perceived. In addition, as with any
interviewer-administered measure, there is always
the possibility that patients will try to provide a
socially desirable response. Nevertheless, given the
corroborating evidence of consistent clinical and
PRO outcomes with the BSW responses, there is
little evidence of such a bias. Furthermore, all three
studies include patients with a verified diagnosis of
OAB; the two studies with all three BSW items
were exclusive to patients with OAB and nocturia
and the third trial required incontinence as a symp-
tom for inclusion. Because of these criteria, the
generalizability of the Satisfaction and Willingness
to Continue items to all OAB patients may be less-
ened though the evidence from these studies sug-
gests that they are robust. Further research will be
required to determine if the BSW measures per-
Table 8 Spearman’s correlations from all three studies
Micturition measures
Patient perception
of treatment benefit†
Patient satisfaction 
with treatment
Patient willingness to 
continue with 
treatment
Study 1 Study 2 Study 3 Study 1 Study 2 Study 1 Study 2
Micturition frequency −0.41 −0.40 −0.32 −0.35 −0.41 −0.34 −0.36
Mean number of nocturia 
episodes per night
−0.41 −0.44 na −0.33 −0.44 −0.29 −0.40
Urgency Levels −0.41 −0.38 na −0.35 −0.38 −0.34 −0.33
Mean number of incontinence
episodes per 24 h
na na −0.30 na na na na
OAB-q
Symptom bother −0.55 −0.49 na −0.46 −0.45 −0.44 −0.32
Coping 0.40 0.33 na 0.33 0.45 0.28 0.28
Concern 0.48 0.36 na 0.41 0.44 0.41 0.36
Sleep 0.59 0.54 na 0.50 0.49 0.46 0.42
Social interaction 0.24  0.09* na 0.24  0.15* 0.22  0.05*
Total scale 0.55 0.46 na 0.46 0.53 0.43 0.39
KHQ
General health perception na −0.12 −0.09 na −0.11 na  −0.04*
Incontinence impact na −0.32 −0.35 na −0.29 na −0.26
Role limitations na −0.23 −0.31 na −0.24 na −0.21
Physical limitations na −0.28 −0.32 na −0.30 na −0.23
Social limitations na −0.30 −0.26 na −0.30 na −0.24
Personal relationships na −0.19 −0.14 na −0.17 na −0.16
Emotions na −0.28 −0.24 na −0.29 na −0.26
Sleep/energy na −0.45 −0.20 na −0.44 na −0.38
Severity measures na −0.23 −0.34 na −0.24 na −0.14
*Correlations were not statistically significant at the P < 0.05.
†Higher score of Benefit Satisfaction and Willingness to Continue reflect higher Benefit, Satisfaction, and Willingness to Continue. OAB-q scoring: Higher symptom
bother scores indicate higher ratings of Symptom Bother whereas higher HRQL subscale scores indicate better HRQL. KHQ scoring: Higher values reflect greater
HRQL impairment.
na, not assessed.
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form as well in other diseases or conditions, par-
ticularly in those with validated, multi-item
satisfaction measures. In addition, it would be
interesting to determine if the BSW results are
affected by the order in which the questions are
asked and interviewer versus self-administered
format.
The BSW is a useful global measure to evaluate
patient perception of treatment outcome. It does
not, however, eliminate the need or value of multi-
item disease-specific measures that provide more
depth and insight into the multiple facets of com-
plex constructs such as HRQL and treatment satis-
faction. Assessing perceived benefit is not the same
as assessing HRQL, nor is the use of the satisfac-
tion with treatment item of the BSW the same as
using a multi-item Satisfaction scale [16]. Global
impression measures and multi-item measures each
have their own place as PROs with strengths and
weaknesses for both measures. In situations where
the effects of a condition are varied and complex,
multi-item measures will demonstrate greater relia-
bility, validity, and responsiveness than single-item
measures [17]. Single-item, global measures are
short, easy to administer and to interpret and may
be useful in conditions with multiple and varied
symptoms (e.g., OAB), and in circumstances where
the construct is an evaluation based on personal
criteria that are not well understood or that vary
from patient to patient (e.g., overall satisfaction).
The choice between single- and multi-item meas-
ures requires a careful consideration of these
factors.
The BSW is a promising tool for both the clinical
and research settings to assist in assessing and
managing treatment outcomes. It is a useful global
impression of three key elements of treatment out-
come: if there was a perceived benefit, if the treat-
ment was satisfactory, and if the patient is willing to
continue the treatment. All three issues, although
related, capture different aspects of the patient’s
perception of a treatment. In addition to informing
researchers in the development of new treatments,
gaining an understanding of patient level percep-
tions can facilitate patient–physician communica-
tion and may increase adherence to prescribed
treatment regimens in practice.
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Appendix A
Benefit, Satisfaction, and Willingness to Continue (BSW) Questions
The following questions are administered by the physician:
BENEFIT—please ask the patient the following question:
1. Have you had any benefit from your treatment?  (0) No  (1) Yes
If YES, please ask the patient the following question:
Have you had little benefit from your treatment or much benefit?  (1) Little benefit
 (2) Much benefit
SATISFACTION—Please ask the patient the following question:
1. Taking all things into account, are you satisfied with your treatment?
 (1) Yes If YES, please ask the patient the following question:
Are you a little satisfied with your treatment or very  (1) A little satisfied
satisfied with your treatment?  (2) Very satisfied
 (0) No If NO, please ask the patient the following question:
Are you a little dissatisfied with your treatment or very  (1) A little dissatisfied
dissatisfied with your treatment?  (2) Very dissatisfied
WILLINGNESS TO CONTINUE
2. Would you be willing to continue treatment with this medication?
 (1) Yes If YES, please as the patient the following question:
Would you be a little bit willing to continue treatment with  (1) A little bit willing
this medication or very willing to continue treatment  (2) Very willing
with this medication?
 (0) No If NO, please ask the patient the following question:
Would you be a little bit unwilling to continue treatment with  (1) A little unwilling
this medication or very unwilling to continue treatment  (2) Very unwilling
with this medication?
